[Hepatogenous diabetes - diagnostics and treatment].
BACKGROUND
Patients with liver cirrhosis develop frequently disturbances of glucose metabolism e. g. glucose intolerance or hepatogenous diabetes which are caused by the hepatocellular functional loss and insulin resistance due to chronic liver disease.


CONCLUSIONS
Until now there are no recommendations comparable to guidelines on the diagnosis of and therapy for hepatogenic diabetes. Regarding basic treatment a sufficient daily energy and protein supply should be guaranteed since the majority of patients with liver cirrhosis are malnourished. The risk of hypoglycaemia must be considered carefully under pharmacological treatment of hepatogenous diabetes. Biguanide and PPAR gamma agonists are contraindicated due to side effects in liver cirrhosis. Suitable oral antidiabetics are glinides and short-acting sulfonylureas. If a sufficient diabetes adjustment does not succeed by oral antidiabetics a prandial insulin therapy using short-acting insulins or rapid-acting insulin analogues should be applied.


CONCLUSIONS
Optimisation of diabetic metabolic conditions is not only important to avoid typical diabetic late complications but also cirrhosis-associated complications, e. g., gastrointestinal bleeding, hepatic encephalopathy or the occurrence of hepatocellular carcinoma.
Gundling
F
F
II. Medizinische Abteilung, Städtisches Krankenhaus München-Bogenhausen. Felix.Gundling@gmx.de
Schumm-Draeger
P M
PM
Schepp
W
W
D000284:Administration, Oral; D001786:Blood Glucose / Q000378:metabolism; D003131:Combined Modality Therapy; D003920:Diabetes Mellitus / Q000175:diagnosis* / Q000209:etiology* / Q000628:therapy; D003927:Diet, Diabetic; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D007333:Insulin Resistance / Q000502:physiology*; D008103:Liver Cirrhosis / Q000150:complications* / Q000175:diagnosis / Q000628:therapy
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin